Is Egrifta (Tesamorelin) Legal in Wisconsin?

The Short Answer: Egrifta Is Legal in Wisconsin

Egrifta (tesamorelin) is a fully legal, FDA-approved prescription drug in Wisconsin. No Wisconsin statute restricts or schedules tesamorelin separately from federal law. A licensed prescriber in Wisconsin can write a prescription for it today, and a licensed pharmacy can fill it.

The key distinction that confuses patients is the difference between FDA-approved tesamorelin (sold as Egrifta or Egrifta SV) and compounded tesamorelin produced at a 503A or 503B facility. Both are legal under federal and Wisconsin law, but the rules governing each pathway differ in important ways covered in detail below.

Federal Legal Status: FDA Approval and Scheduling

FDA Approval History

The FDA approved tesamorelin acetate under the brand name Egrifta on November 10, 2010, under New Drug Application (NDA) 022505 [1]. The approval was granted to Theratechnologies Inc. For a single indication: reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. A reformulated product, Egrifta SV (2 mg/vial lyophilized powder), received FDA approval in June 2019, replacing the original 1 mg/vial formulation [2].

Because tesamorelin has a specific approved indication, it occupies a well-defined regulatory category. It is not a research chemical operating in a gray area.

Controlled Substance Status

Tesamorelin is not scheduled under the federal Controlled Substances Act. The Drug Enforcement Administration (DEA) has placed no scheduling restriction on it. The FDA's list of bulk drug substances that may be used in compounding (the "503A bulks list" and "503B bulks list") does not prohibit tesamorelin from compounding, though compounded versions must still meet USP standards and originate from FDA-registered facilities [3].

Growth hormone itself (somatropin) is a Schedule III controlled substance when compounded without FDA approval. Tesamorelin is not somatropin. It is a synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates the pituitary to produce endogenous growth hormone. That pharmacological distinction matters legally: tesamorelin does not fall under the anabolic steroid or somatropin-specific restrictions that apply to other peptides in the GH axis [4].

FDA Enforcement Posture on Compounded Tesamorelin

The FDA has, at various points, issued guidance discouraging the compounding of drugs that are commercially available in an FDA-approved form. Egrifta SV is commercially available. As a result, 503A compounding pharmacies face scrutiny if they compound tesamorelin without a patient-specific medical need that the commercial product cannot meet (such as a documented allergy to an excipient in Egrifta SV). The FDA's guidance document "Compounding Under the Federal Food, Drug, and Cosmetic Act" outlines these conditions [5].

This is not a Wisconsin-specific legal barrier. It is a federal compounding framework issue that applies in all 50 states.

Wisconsin State Legal Framework

Wisconsin Controlled Substances Act

Wisconsin Statutes Chapter 961 governs controlled substances in the state. Tesamorelin does not appear in any schedule under Chapter 961. The Wisconsin Department of Safety and Professional Services (DSPS) and the Wisconsin Pharmacy Examining Board have not issued any state-specific scheduling action or restriction on tesamorelin [6]. A prescriber writing for Egrifta in Wisconsin does not need a DEA controlled substance registration for that prescription specifically, though maintaining an active DEA registration is standard practice for most clinicians regardless.

Wisconsin Medical Practice Act and Prescriber Authority

Under Wisconsin Statutes § 448.03, licensed physicians (MD and DO) hold authority to prescribe any FDA-approved or legally compoundable drug for any condition they deem medically appropriate, including off-label uses. Advanced practice nurse prescribers (APNPs) and physician assistants (PAs) with prescriptive authority have equivalent rights under their respective practice statutes (Wis. Stat. § 441.16 and § 448.9714) [7].

Off-label prescribing of tesamorelin (for example, for non-HIV-related growth hormone deficiency or body composition concerns) is legally permissible under Wisconsin law. The FDA's approved labeling binds manufacturers, not physicians. The Wisconsin Medical Examining Board does not prohibit off-label prescribing.

Wisconsin Pharmacy Board Rules

The Wisconsin Pharmacy Examining Board, operating under Wis. Admin. Code Phar ch. 1 through 18, requires that all dispensed medications come from a licensed pharmacy. Compounding pharmacies operating in Wisconsin must hold a valid Wisconsin permit and comply with USP 795 (non-sterile) or USP 797 (sterile) standards as applicable. Tesamorelin injections are sterile preparations and therefore fall under USP 797 requirements [8].

Out-of-state compounding pharmacies shipping tesamorelin into Wisconsin must hold a non-resident pharmacy permit issued by the Wisconsin Pharmacy Examining Board. Patients receiving mail-order tesamorelin should verify that the dispensing pharmacy holds this permit before accepting a shipment.

Telehealth Prescribing in Wisconsin

Wisconsin enacted telehealth legislation under Wis. Stat. § 448.9744, which permits licensed clinicians to prescribe within a valid clinician-patient relationship established via synchronous audio-video technology. A Wisconsin clinician using a telehealth platform can prescribe Egrifta to a Wisconsin patient without an in-person visit, provided the clinician performs an adequate evaluation, documents medical necessity, and meets the standard of care applicable to in-person prescribing [9].

Telehealth prescriptions for tesamorelin are subject to the same documentation requirements as in-person prescriptions. The clinician must document the indication, the clinical rationale, and patient education about injection technique and side effects.

How to Get Egrifta (Tesamorelin) in Wisconsin

Step 1: Establish Medical Eligibility

The FDA-approved indication is HIV-associated lipodystrophy. Clinicians diagnosing excess visceral adiposity in this population typically use waist circumference measurements and sometimes trunk-to-limb fat ratio via DEXA scan. The key Phase 3 trial (LIPO-010, N=412) demonstrated that tesamorelin 2 mg daily produced a statistically significant reduction in visceral adipose tissue (VAT) area of 18.1% versus 5.1% placebo at 26 weeks (P<0.001) [10].

For off-label use, the eligibility assessment varies by the prescribing clinician's clinical judgment. Some hormone-specialist physicians prescribe tesamorelin off-label for growth hormone deficiency in adults when growth hormone secretagogue testing supports a diagnosis of relative deficiency. That decision involves a full history, physical exam, and often IGF-1 measurement.

Step 2: Find a Qualified Prescriber in Wisconsin

Several prescriber types can initiate tesamorelin in Wisconsin:

• Infectious disease physicians who manage HIV-positive patients with lipodystrophy
• Endocrinologists evaluating body composition and growth hormone axis disorders
• Hormone medicine specialists (often internal medicine or family medicine physicians with additional training)
• Telehealth providers licensed in Wisconsin through platforms specializing in hormone and metabolic health

The Endocrine Society's 2014 clinical practice guideline on growth hormone deficiency in adults states: "We recommend testing for GHD in patients with hypothalamic-pituitary disease, history of cranial irradiation, or traumatic brain injury, as these are the highest-risk populations." [11] This guideline provides a clinical framework that many Wisconsin providers use when evaluating off-label candidates.

Step 3: Obtain the Prescription and Choose a Dispensing Route

Once a prescription is written, patients have three legal dispensing options in Wisconsin:

Option A: Branded Egrifta SV from a Retail or Specialty Pharmacy Egrifta SV is the FDA-approved commercial product. Specialty pharmacies including those contracted with Theratechnologies' patient access program can dispense it. Insurance coverage for the HIV-lipodystrophy indication is available through most major Wisconsin Medicaid plans and many private insurers, though prior authorization is typically required.

Option B: 503A Compounding Pharmacy A 503A pharmacy can compound tesamorelin for a specific patient when there is a valid patient-specific reason the commercial product is unsuitable. The patient needs a written prescription. The pharmacy must be Wisconsin-licensed or hold a Wisconsin non-resident permit. Cost is often lower than branded Egrifta SV, but the compounded product lacks FDA approval of that specific formulation.

Option C: 503B Outsourcing Facility A 503B outsourcing facility can produce tesamorelin in bulk without patient-specific prescriptions but must register with the FDA and meet Current Good Manufacturing Practice (CGMP) standards. Healthcare practitioners (not patients directly) typically order from 503B facilities, making this route most relevant to clinics that administer the drug in-office.

Step 4: Learn Correct Injection Technique

Tesamorelin 2 mg is reconstituted with the supplied sterile water and injected subcutaneously into the abdomen daily. Patients should rotate injection sites and avoid areas of lipodystrophy. Common injection-site reactions include erythema, pruritus, and induration, reported in 24.8% of tesamorelin-treated patients versus 7.0% of placebo patients in controlled trials [10].

Clinical Evidence Supporting Tesamorelin Use

Primary Efficacy Data

The two key Phase 3 trials (LIPO-010, N=412, and a second 52-week extension study) form the core evidence base for FDA approval. In LIPO-010, tesamorelin 2 mg daily reduced VAT area by 18.1% at 26 weeks compared with 5.1% in the placebo group (P<0.001), and trunk fat mass fell by 1.76 kg versus 0.47 kg [10]. These results supported the FDA's 2010 approval.

A separate Phase 3b trial published in the Journal of Acquired Immune Deficiency Syndromes (N=273) confirmed that the VAT reduction was maintained at 52 weeks in patients who continued therapy, while discontinuation led to partial rebound of VAT within 26 weeks [12]. This rebound effect is clinically meaningful: patients considering tesamorelin should understand it is a maintenance therapy, not a one-time intervention.

IGF-1 Monitoring

Tesamorelin raises IGF-1 concentrations. The prescribing information recommends baseline IGF-1 measurement and monitoring during therapy [2]. Elevated IGF-1 is not an absolute contraindication, but patients with active malignancy should not receive tesamorelin because IGF-1 promotes cellular proliferation. The FDA label carries a contraindication for active malignancy and for patients with disruption of the hypothalamic-pituitary axis due to hypophysectomy, hypopituitarism, or pituitary tumor.

Cardiovascular and Metabolic Profile

Tesamorelin has a neutral-to-modest favorable effect on triglycerides in HIV-lipodystrophy patients, with a mean reduction of approximately 50 mg/dL in patients with baseline hypertriglyceridemia in the LIPO-010 trial [10]. Fasting glucose and insulin sensitivity showed no statistically significant worsening in controlled trials at 26 weeks, though clinicians monitor HbA1c at baseline and periodically during therapy given GH's known counter-regulatory effects on insulin.

Common Legal Misconceptions About Tesamorelin in Wisconsin

"Tesamorelin Is a Controlled Peptide Like BPC-157"

This is incorrect. BPC-157 has no FDA approval and exists in a genuine regulatory gray area. Tesamorelin holds full FDA approval under NDA 022505. The two compounds have entirely different legal statuses.

"You Can Only Get It for HIV"

The FDA label restricts the manufacturer's marketing claims. Physicians are free to prescribe off-label. No Wisconsin statute prohibits a clinician from prescribing Egrifta for a non-HIV patient when clinical judgment supports it. The American Association of Clinical Endocrinologists (AACE) acknowledges off-label peptide use in body composition management as a growing area of clinical practice [13].

"Compounded Tesamorelin Is Illegal"

Compounded tesamorelin is not automatically illegal. It occupies a regulated space under 503A and 503B of the Food, Drug, and Cosmetic Act. The risk of enforcement increases when the commercial product is available and no specific patient need for compounding exists. Working with a pharmacy that documents clinical rationale for compounding reduces this risk substantially.

"Telehealth Prescribing of Tesamorelin Is Not Allowed"

Telehealth prescribing is explicitly permitted in Wisconsin under Wis. Stat. § 448.9744. No federal or Wisconsin law separately restricts telehealth prescribing of non-controlled substances like tesamorelin. A clinician using a compliant telehealth platform who performs an adequate evaluation may prescribe Egrifta or compounded tesamorelin without an in-person visit.

What Prescribers Need to Document

Regardless of the indication (on-label or off-label), Wisconsin prescribers should document:

1. The specific diagnosis or clinical rationale (e.g., HIV-associated lipodystrophy confirmed on imaging, or adult growth hormone deficiency supported by IGF-1 and stimulation testing)
2. Baseline measurements: waist circumference or VAT on imaging, IGF-1 level, fasting glucose, HbA1c, and a current malignancy screen
3. Patient education: injection technique, side-effect profile, the expected timeline for VAT reduction (typically 3 to 6 months for meaningful effect), and the likelihood of VAT rebound on discontinuation
4. A monitoring plan: IGF-1 at 3 months, then every 6 months; glucose monitoring per diabetes risk; and reassessment of continued clinical benefit at 6-month intervals

The Endocrine Society's 2019 update on evaluation and management of adult growth hormone deficiency provides a framework for monitoring GH-axis peptide therapies, noting that "IGF-1 levels should be maintained within age-appropriate reference ranges during treatment." [14]

Insurance, Cost, and Patient Assistance in Wisconsin

Branded Egrifta SV carries a list price exceeding $3,000 per month. For Wisconsin Medicaid enrollees with an HIV diagnosis and documented lipodystrophy, coverage is generally available under the HIV/AIDS Drug Assistance Program (ADAP) administered through the Wisconsin Division of Public Health. Private insurer coverage requires prior authorization documenting an HIV diagnosis and clinical findings consistent with lipodystrophy.

Theratechnologies operates a patient support program ("TheraCom") that assists with prior authorization, appeals, and co-pay assistance for commercially insured patients. Patients who do not qualify for on-label coverage and are using tesamorelin off-label typically pay out-of-pocket for compounded versions, which range from $150 to $400 per month depending on the compounding pharmacy and vial concentration.